Breaking News Instant updates and real-time market news.

CI

Cigna

$187.86

-1.33 (-0.70%)

, ESRX

Express Scripts

$76.84

-0.675 (-0.87%)

06:27
08/07/18
08/07
06:27
08/07/18
06:27

Icahn: Cigna 'dramatically' overpaying for 'highly challenged' Express Scripts

Carl Icahn released an open letter to stockholders of Cigna (CI), which states in part: "Cigna is dramatically overpaying for a highly challenged Express Scripts (ESRX) that is facing existential risks on several fronts. Regulatory risk due to opposition to the highly flawed rebate system will likely lower Express Scripts' profitability dramatically. As a long-time trustee at Mount Sinai Medical Center and a major supporter of the Icahn School of Medicine at Mount Sinai, I have seen first-hand the significant problem of prescription drug pricing in America today. This is a critical issue that must be addressed and eliminating conflicting reward systems and over-earning middlemen is the logical first step. Competitive risk from Amazon (AMZN), arguably the strongest competitor in the world, will be an existential threat to PBMs like Express Scripts, possibly challenging their very existence.Express Scripts could lose more customers like Anthem (ANTM) as it ceases to be independent and certain large MCOs and affiliated plans do not wish to deal with a company which is owned by one of their competitors. With Cigna's likely standalone value today of $215 and Express Scripts' likely standalone value less than $60, it's a travesty to complete this deal. Paying an over 50% premium to a company whose very existence may be challenged is a potentially massive destruction of Cigna shareholder value. The only shareholders we believe would vote for this very risky acquisition are those who also own Express Scripts and are desperate to save it even at the expense of losing a great deal of value in their Cigna investment. We hope and believe that many of these 'crossover' shareholders have used this great opportunity to sell their Express Scripts shares and vote 'against' this transaction.As an alternative, we believe Cigna should pursue a multi-year partnership with an existing PBM provider, potentially Express Scripts, while the industry resolves the structural challenges mentioned here. During this time, management can further develop or acquire their own PBM capabilities optimized for the rapidly changing regulatory and competitive environment. However, it should be noted that Cigna has done very well on its own and there may well not be a need for PBM capabilities once the landscape changes and/or Amazon and other competitors materialize. Additionally, we would like to see Cigna use the cash portion of the Express Scripts consideration and free cash flow to aggressively repurchase its own shares. We believe this could result in a Cigna target price of over $250 in a reasonable time frame."

CI

Cigna

$187.86

-1.33 (-0.70%)

ESRX

Express Scripts

$76.84

-0.675 (-0.87%)

AMZN

Amazon.com

$1,847.75

24.46 (1.34%)

ANTM

Anthem

$258.22

0.14 (0.05%)

  • 16

    Aug

  • 24

    Aug

  • 24

    Aug

  • 13

    Sep

CI Cigna
$187.86

-1.33 (-0.70%)

08/03/18
RHCO
08/03/18
NO CHANGE
Target $244
RHCO
Buy
Cigna price target raised to $244 from $220 at SunTrust
SunTrust analyst David MacDonald raised his price target on Cigna (CI) to $244 and kept his Buy rating after its "strong" Q2 results showed a "sizable" earnings beat across its business lines and lower expected medical cost trends. The analyst also maintains his bullish view on the pending Express Scripts (ESRX) deal, stating that the potential benefits of the combination are underappreciated give the strong momentum of the latter heading into 2019. MacDonald contends that investors' merger related concerns are "misplaced" and also sees Cigna valuation as "compelling".
08/02/18
JPMS
08/02/18
NO CHANGE
JPMS
Overweight
Cigna holders unlikely to vote down Express Scripts deal, says JPMorgan
While Cigna (CI) shares have underperformed peers since the deal for Express Scripts (ESRX) was announced in March, shareholders are unlikely to vote down the transaction, JPMorgan analyst Gary Taylor tells investors in a research note after the Wall Street Journal reported that Carl Icahn has built a stake and will push for voting against the deal. The analyst admits the market is taking a more negative view, as Express Scripts' 16% spread to offer value widened to 25% yesterday. Taylor believes few shareholders have questioned the strategic rational of the merger. He believes, however, that some of Icahn's points could resonate with bears in the near-term. The analyst keeps an Overweight rating on Cigna.
08/02/18
SBSH
08/02/18
NO CHANGE
SBSH
Vote against Express Scripts deal 'somewhat shortsighted,' says Citi
Citi analyst Ralph Giacobbe believes a vote against Cigna's (CI) proposed acquisition of Express Scripts (ESRX), which the Wall Street Journal reported that activist Carl Icahn will push for, could prove "somewhat shortsighted given the changing and evolving healthcare landscape and the integrated offering and cash flow that a combined entity would generate to compete more effectively." The analyst says that regardless of the outcome, he remains positive on Cigna shares. The company's model should continue to drive growth without Express Scripts, and potentially enhance growth with the deal, Giacobbe tells investors in a research note. He keeps a Buy rating on Cigna.
07/20/18
BARD
07/20/18
DOWNGRADE
Target $81
BARD
Neutral
Express Scripts downgraded to Neutral amid 'heavy political attack' at Baird
As reported previously, Baird analyst Eric Coldwell downgraded Express Scripts (ESRX) to Neutral from Outperform as he believes the PBMs have been under heavy political attack in recent weeks and the stand-alone trajectory is hard to model right now. He said the share price upside is largely reliant on the successful completion of the Cigna (CI) transaction and downside risks have significantly increased. Coldwell has an $81 price target on Express Scripts shares.
ESRX Express Scripts
$76.84

-0.675 (-0.87%)

07/20/18
07/20/18
NO CHANGE

Fly Intel: Today's top analyst calls on Wall Street
Check out today's top analyst calls from around Wall Street, compiled by The Fly. BOFA CUTS YUM CHINA TO UNDERPERFORM: BofA Merrill Lynch analyst Chen Luo downgraded Yum China (YUMC) to Underperform from Neutral and cut its price target to $34 from $44.30. Luo said he expects Yum China to continue to underperform given a likely peak in KFC trends amid China's weakening macro environment, a likely prolonged turnaround at Pizza Hut combined with heavy costs, a slowdown in Chinese consumer consumption, and RMB depreciation. Yum China is down 4.8% in late morning trading. CREDIT SUISSE CUTS FIVE BELOW TO NEUTRAL: Credit Suisse analyst Judah Frommer downgraded Five Below (FIVE) to Neutral from Outperform, telling investors that he is moving to the sidelines as he sees risk/reward balanced at current levels given the stock's material outperformance and back-half comp acceleration that he believes is priced into shares. Frommer keeps his $110 price target and says Five Below remains one of the most differentiated concepts in retail. Five Below is down 4.4% in late morning trading. BAIRD MORE CAUTIOUS ON DRUG SUPPLY CHAIN: Baird analyst Eric Coldwell downgraded Express Scripts (ESRX), AmerisourceBergen (ABC), and McKesson (MCK), all to Neutral from Outperform, citing the heavy political attack in recent weeks against pharmacy benefit managers and members of the drug supply chain. Among them, he said AmerisourceBergen remains his preferred name, but he cannot justify putting new money to work in these names in the current environment. SUNTRUST STARTS VIKING WITH A BUY: SunTrust analyst Edward Nash initiated Viking Therapeutics (VKTX) with a Buy rating and a price target of $14, saying its VK2809 drug for lipid disorders "has the potential to become a promising treatment by addressing multiple metabolic issues" associated with the non-alcoholic steatohepatitis disease, or NASH. Viking is up 8.3% in late morning trading. JPMORGAN SAYS BUY GM, SELL TESLA INTO EARNINGS: JPMorgan analyst Ryan Brinkman forecast lower than consensus Q2 earnings for Ford (F) and higher than consensus earnings for General Motors (GM). The analyst is also concerned about the potential for a "large loss and accompanying large cash outflow" at Tesla (TSLA) in Q2 to "make the bridge" to GAAP profitability and positive cash generation in the second half of the year. Brinkman maintained Overweight ratings on GM and Ford, with a preference for GM shares. He also kept his cautious Underweight rating on Tesla shares, seeing 44% downside to his $180 December 2018 price target.
AMZN Amazon.com
$1,847.75

24.46 (1.34%)

08/03/18
BARD
08/03/18
NO CHANGE
Target $2100
BARD
Outperform
Amazon summit highlights long cloud growth runway, says Baird
After having attended the AWS Summit in Chicago this week, Baird analyst Colin Sebastian said his talks with several enterprise IT decision makers highlight Amazon's "clear advantage" in product breadth and go-to-market capabilities despite the fact that cloud services competition is "undoubtedly intensifying" from Microsoft's (MSFT) Azure and Alphabet's (GOOGL) Google Cloud Platform. Most large-scale enterprises are still in the early days of cloud migration, which bodes well for the long-term growth outlook for AWS along with Azure and Google Cloud, Sebastian concluded. He keeps an Outperform rating and $2,100 price target on Amazon shares.
08/06/18
MSCO
08/06/18
NO CHANGE
MSCO
Boeing, Tesla, Nvidia make Morgan Stanley 'key man risk' list
Morgan Stanley equity strategist Mark Savino noted that about 12% of CEO jobs among S&P 500 companies turned over in 2017, noting that this was the highest level of CEO departures since before the financial crisis. The 59 stocks of S&P 500 companies that had CEOs depart in 2017 underperformed the market by 11% over the next 12 months, or since the departure for instances that were less than 12 months ago, noted Savino. In cooperation with the firm's U.S. analysts, Savino and his team identified the companies in each sector they believe face the greatest level of "key man risk," which includes: Boeing (BA), Tesla (TSLA), ADT Inc. (ADT), Moody's (MCO), TransUnion (TRU), Arista Networks (ANET), Church & Dwight (CHD), Coca-Cola (KO), Monster Beverage (MNST), Coupa Software (COUP), Salesforce (CRM), FireEye (FEYE), MongoDB (MDB), Microsoft (MSFT), New Relic (NEWR), XPO Logistics (XPO), Hilton (HLT), Las Vegas Sands (LVS), Best Buy (BBY), Ulta (ULTA), Aflac (AFL), Athene Holding (ATH), Lincoln National (LNC), Arthur J. Gallagher (AJG), Chubb (CB), Amazon.com (AMZN), Activision Blizzard (ATVI), Facebook (FB), Alphabet (GOOGL), Apple (AAPL), Terex (TEX), Cleveland-Cliffs (CLF), Freeport McMoRan (FCX), FleetCor (FLT), Global Payments (GPN), Square (SQ), Jazz Pharmaceuticals (JAZZ), Cheesecake Factory (CAKE), Broadcom (AVGO), Nvidia (NVDA), Chegg (CHGG), DXC Technology (DXC), Medidata (MDSO), Pluralsight (PS), RealPage (RP), Shopify (SHOP) and T-Mobile (TMUS).
08/06/18
LOOP
08/06/18
NO CHANGE
Target $55
LOOP
Buy
Etsy price target raised to $55 from $50 at Loop Capital
Loop Capital analyst Laura Champine raised her price target on Etsy (ETSY) to $55 and kept her Buy rating after its Q2 earnings beat and raised guidance. The analyst notes that while the stock price has already doubled year-to-date, its positive momentum is likely to continue after another update forecasting continued revenue growth. Champine also believes that her revenue growth forecasts may prove to be conservative, as Etsy's holiday promotional activity later this year is likely to increase seller count. The analyst contends that Etsy's seller fees at 5% are also an "excellent value" relative to eBay's (EBAY) 10% and Amazon's (AMZN) 15%.
08/06/18
STFL
08/06/18
NO CHANGE
Target $202
STFL
Buy
Facebook added to Stifel Select List, Amazon removed
Stifel analyst Scott Devitt replaced Amazon (AMZN) with Facebook (FB) on the Stifel Select List, citing the strong year-to-date performance of Amazon shares, which he still likes and keeps a Buy rating upon. He believes Facebook expectations, and the shares, are appropriately set to allow for longer-term outperformance given the material reset that followed the company's "painful" Q2 update, Devitt tells investors. He maintains a Buy rating and $202 price target on Facebook.
ANTM Anthem
$258.22

0.14 (0.05%)

07/09/18
BMOC
07/09/18
UPGRADE
BMOC
Outperform
Anthem upgraded to Outperform from Market Perform at BMO Capital
07/09/18
BMOC
07/09/18
UPGRADE
Target $290
BMOC
Outperform
Anthem upgraded to Outperform at BMO Capital on strong earnings view
As reported earlier, BMO Capital analyst Matt Borsch upgraded Anthem to Outperform from Market Perform and raised his price target to $290 from $275, saying he expects the company to post strong earnings growth over the next 4-5 years and execute under the new CEO Gail Boudreaux. The analyst cites his recent meetings with the company which boosted his confidence in Anthem driving higher earnings from the realization of annual savings in pharmacy costs, its partnerships and new fee-based arrangements with other health plans, as well as a deeper penetration of its "massive" employer customer base through "aggressive cross-selling of specialty product". Borsch also expects the company to capture a "substantial share of the five-year pipeline of $80 billion in expected new Medicaid revenue".
07/09/18
JPMS
07/09/18
NO CHANGE
JPMS
CMS suspension could save Molina, Centene hundreds of millions, says JPMorgan
The Centers for Medicare and Medicaid Services confirmed Saturday that it will at least temporarily suspend the healthcare exchange risk adjustment program. If true, the immediate effect is that this Fall Molina Healthcare (MOH) and Centene (CNC) would avoid paying hundreds of millions of accrued payments related to 2017, JPMorgan analyst Gary Taylor tells investors in a research note. He notes that Molina would avoid $912M in payments and Centene $677M, according to their annual filings. On the other side, Anthem (ANTM) would not collect an expected $400M-$500M receivable, Taylor adds, citing his estimate. The analyst believes the longer-term effect of suspension "would be possibly additional significant disruption/withdrawals/rate hikes in the individual market for 2018-19." 19. If permanently dismantled, Taylor estimates Molina could book a one-time $350M after-tax gain related to 2017, Centene no gain and Anthem a $320M after tax loss. In terms of recurring earnings power exposure to exchanges, the analyst believes only Molina could materially benefit.
06/28/18
CANT
06/28/18
NO CHANGE
CANT
Amazon deal not to materially impact managed care segment, says Cantor Fitzgerald
Following the announcement that Amazon (AMZN) is acquiring PillPack, Cantor Fitzgerald analyst Steven Halper notes that back in April, CNBC had reported that Walmart (WMT) and Amazon were both looking to acquire the company, with Walmart likely to pay under $1B for PillPack. At this juncture, the analyst is not worried about Amazon's entrance into the prescription market and does not expect a material impact on any of the companies he covers in the managed care segment. Halper reiterates an Overweight rating of Aetna (AET), Anthem (ANTM), Centene (CNC), UnitedHealth (UNH) and Wellcare (WCG). He keeps a Neutral rating on Humana (HUM).

TODAY'S FREE FLY STORIES

MSI

Motorola Solutions

$129.97

0.72 (0.56%)

18:48
11/16/18
11/16
18:48
11/16/18
18:48
Hot Stocks
Motorola Solutions: ITC confirms Hytera products infringe Motorola patents »

Motorola Solutions…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Nov

  • 18

    Dec

  • 19

    Dec

PCG

PG&E

$24.39

6.62 (37.25%)

18:23
11/16/18
11/16
18:23
11/16/18
18:23
Periodicals
CPUC isn't ruling out board shuffle, breakup for PG&E, Bloomberg says »

The California Public…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ABX

Barrick Gold

$13.04

0.05 (0.38%)

18:00
11/16/18
11/16
18:00
11/16/18
18:00
Periodicals
Barrick Gold looking to add more copper, bullion assets, Reuters reports »

Barrick Gold is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WTR

Aqua America

$33.05

0.165 (0.50%)

17:57
11/16/18
11/16
17:57
11/16/18
17:57
Hot Stocks
Aqua America CEO acquires over 25,000 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLRE

Real Estate SPDR

$33.45

0.445 (1.35%)

, XLB

S&P Select Materials SPDR

$55.23

0.53 (0.97%)

17:39
11/16/18
11/16
17:39
11/16/18
17:39
General news
Week ending ETF scorecard: Real Estate leads, Consumer Discretionary slumps »

S&P500 SECTORS: Real…

XLRE

Real Estate SPDR

$33.45

0.445 (1.35%)

XLB

S&P Select Materials SPDR

$55.23

0.53 (0.97%)

XLU

Utilities SPDR

$54.86

0.77 (1.42%)

XLI

Industrial Select Sector SPDR

$72.00

(0.00%)

XLV

Health Care Select Sector SPDR

$92.05

0.91 (1.00%)

XLF

Financial Select Sector

$26.78

0.03 (0.11%)

XLP

Consumer Staples Sector SPDR

$56.04

0.15 (0.27%)

XLE

Energy Select Sector SPDR

$67.23

0.76 (1.14%)

XLC

Communication Services Select Sector SPDR Fund

$44.88

-0.2 (-0.44%)

XLK

Technology Select Sector SPDR

$68.22

-0.1 (-0.15%)

XLY

Consumer Discretionary Sector SPDR

$106.37

-0.43 (-0.40%)

GLD

SPDR Gold Shares

$115.56

0.82 (0.71%)

SLV

iShares Silver Trust

$13.55

0.115 (0.86%)

USO

United States Oil Fund

$12.07

0.08 (0.67%)

UNG

United States Natural Gas Fund

$35.43

3.63 (11.42%)

HYG

iShares iBoxx $ High Yield Corporate Bond

$83.24

-0.27 (-0.32%)

LQD

iShares iBoxx $ Investment Grade Corporate Bond

$111.73

0.23 (0.21%)

TLT

iShares 20+ Year Treasury Bond Fund

$114.65

0.61 (0.53%)

IEF

iShares 7-10 Year Treasury Bond ETF

$101.13

0.3 (0.30%)

SHY

iShares 1-3 Year Treasury Bond

$83.13

0.08 (0.10%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AQST

Aquestive Therapeutics

$17.02

0.23 (1.37%)

17:36
11/16/18
11/16
17:36
11/16/18
17:36
Hot Stocks
Aquestive receives CRL from FDA for tadalafil oral film »

Aquestive Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jan

DAKT

Daktronics

$7.67

0.07 (0.92%)

17:35
11/16/18
11/16
17:35
11/16/18
17:35
Hot Stocks
Daktronics adopts new shareholder rights agreement »

Daktronics announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

TI

Telecom Italia

$6.02

0.12 (2.03%)

17:33
11/16/18
11/16
17:33
11/16/18
17:33
Periodicals
Gubitosi viewed as frontrunner for Telecom Italia CEO job, Reuters says »

Veteran Italian manager…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MAXR

Maxar Technologies

$18.77

-0.59 (-3.05%)

17:30
11/16/18
11/16
17:30
11/16/18
17:30
Hot Stocks
Maxar Technologies shareholders approve U.S. domestication »

Maxar Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PLUG

Plug Power

$1.83

(0.00%)

17:28
11/16/18
11/16
17:28
11/16/18
17:28
Syndicate
Breaking Syndicate news story on Plug Power »

Plug Power files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GSB

GlobalSCAPE

$4.55

-0.02 (-0.44%)

17:22
11/16/18
11/16
17:22
11/16/18
17:22
Syndicate
Breaking Syndicate news story on GlobalSCAPE »

GlobalSCAPE files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EQIX

Equinix

$388.18

2.67 (0.69%)

17:19
11/16/18
11/16
17:19
11/16/18
17:19
Hot Stocks
Equinix's Lee sells 2,792 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Nov

  • 10

    Dec

LMT

Lockheed Martin

$301.06

-4.42 (-1.45%)

17:17
11/16/18
11/16
17:17
11/16/18
17:17
Hot Stocks
Lockheed Martin awarded $282.09M Naval Sea Systems Command contract »

Lockheed Martin has been…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TLGT

Teligent

$2.56

0.045 (1.79%)

17:16
11/16/18
11/16
17:16
11/16/18
17:16
Hot Stocks
Teligent receives notification of deficiency from Nasdaq »

Teligent said that on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

STAF

Staffing 360 Solutions

$1.82

0.07 (4.00%)

17:16
11/16/18
11/16
17:16
11/16/18
17:16
Syndicate
Breaking Syndicate news story on Staffing 360 Solutions »

Staffing 360 Solutions…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

IMMR

Immersion

$9.56

-0.14 (-1.44%)

17:12
11/16/18
11/16
17:12
11/16/18
17:12
Hot Stocks
Breaking Hot Stocks news story on Immersion »

Man Group reports 4.84%…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ATNX

Athenex

$11.95

0.74 (6.60%)

17:10
11/16/18
11/16
17:10
11/16/18
17:10
Hot Stocks
Breaking Hot Stocks news story on Athenex »

Perceptive Advisors…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

  • 02

    Dec

TSRO

Tesaro

$34.96

8.39 (31.58%)

17:08
11/16/18
11/16
17:08
11/16/18
17:08
Recommendations
Tesaro analyst commentary  »

Piper Jaffray says…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Dec

EEI

Ecology & Environment

$10.50

-2 (-16.00%)

17:05
11/16/18
11/16
17:05
11/16/18
17:05
Hot Stocks
Ecology & Environment receives noncompliance notice from Nasdaq »

Ecology and Environment…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AEE

Ameren

$69.29

0.01 (0.01%)

16:58
11/16/18
11/16
16:58
11/16/18
16:58
Hot Stocks
Ameren exec Nelson sells $690,000 worth of common shares »

Ameren SVP, general…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EQS

Equus II Inc

$1.86

(0.00%)

16:56
11/16/18
11/16
16:56
11/16/18
16:56
Hot Stocks
Equus II Inc reports net assets of $46.6M as of September 30 »

Equus Total Return…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VAPO

Vapotherm

$17.10

-0.42 (-2.40%)

16:56
11/16/18
11/16
16:56
11/16/18
16:56
Hot Stocks
Breaking Hot Stocks news story on Vapotherm »

Redmile Group reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

COTY

Coty

$9.09

0.39 (4.48%)

16:55
11/16/18
11/16
16:55
11/16/18
16:55
Hot Stocks
Coty CEO acquires 2.3M common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Mar

NVS

Novartis

$87.74

0.52 (0.60%)

16:54
11/16/18
11/16
16:54
11/16/18
16:54
Upgrade
Novartis rating change at Goldman Sachs »

Novartis upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Dec

  • 03

    Dec

VIAB

Viacom

$33.00

1.13 (3.55%)

16:52
11/16/18
11/16
16:52
11/16/18
16:52
Syndicate
Breaking Syndicate news story on Viacom »

Viacom files automatic…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Nov

  • 04

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.